Microbiota and Mycobiota in Chronic Inflammatory Demyelinating Polyneuropathy

32 treatment-naive CIDP patients and 15 healthy controls were enrolled, with samples including stool, serum, and cerebrospinal fluid. The dataset contains results from amplicon sequencing of bacterial and fungal communities, SCFA quantification, and IL18 promoter genotyping, correlated with clinical and electrophysiological measures. It was authored by Szymon Andrusiów and last updated in June 2026.

Use Cases

• Correlating gut bacterial alpha diversity with nerve conduction study abnormalities based on the described findings.
• Identifying taxonomic enrichments or depletions (e.g., Hominisplanchenecus_A faecis) in CIDP patients versus controls.
• Investigating associations between short-chain fatty acid concentrations and microbial diversity indices across stool, serum, and CSF.
• Examining links between IL18 promoter haplotypes and distinct microbial community signatures.

Strengths

• Includes multi-omics data from 47 total subjects (32 patients, 15 controls) across stool, serum, and CSF.
• Correlates microbiome and mycobiome profiles with specific clinical, electrophysiological, and laboratory parameters.
• Uses standardized bioinformatic processing (QIIME2) and differential abundance testing (ANCOM BC2).
• Published under a permissive CC-BY-4.0 license.

Limitations

• Row count and column-level documentation are absent; field semantics must be inferred after download.
• The dataset is small (26.3 KB), indicating limited scope and likely summary-level results rather than raw sequence data.
• Data may reflect bias inherent to the specific cohort and study design described.

Provenance

Source

figshare

Collection Method

Clinical study with sample collection, amplicon sequencing (16S rRNA, ITS1), genotyping, and metabolite quantification.

Freshness

Last updated 2026-06-03 06:04:52; freshness should be verified.